drugset / Trial / NCT05164978
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for EBV associated hemophagocytic lymphohistiocytosis.
Timeline
- Start
- 2021-05-01
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Methylprednisolone | Other / unclassified | 0.25 mg/kg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |